Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Leukemia

  Free Subscription


18.10.2021

1 Am J Hematol
2 Ann Hematol
2 Blood
8 Bone Marrow Transplant
1 Cancer
1 Eur J Immunol
3 Exp Hematol
1 Int J Hematol
1 J Clin Oncol
1 J Natl Cancer Inst
2 Leuk Lymphoma
1 Leukemia
1 Oncogene
2 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Hematol

  1. HALLEK M, Al-Sawaf O
    Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.
    Am J Hematol. 2021 Oct 9. doi: 10.1002/ajh.26367.
    PubMed         Abstract available


    Ann Hematol

  2. HOU HA, Tzeng HE, Liu HY, Chou WC, et al
    Effectiveness of induction regimens on survival outcome in acute myeloid leukemia patients: a real-world data from 2001 to 2015.
    Ann Hematol. 2021 Oct 13. pii: 10.1007/s00277-021-04670.
    PubMed         Abstract available

  3. PASVOLSKY O, Shimony S, Ram R, Shimoni A, et al
    Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study.
    Ann Hematol. 2021 Oct 9. pii: 10.1007/s00277-021-04693.
    PubMed         Abstract available


    Blood

  4. KENNEDY GA, Tey SK, Buizen L, Varelias A, et al
    A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis.
    Blood. 2021;137:1970-1979.
    PubMed         Abstract available

  5. GEMENETZI K, Psomopoulos F, Carriles AA, Gounari M, et al
    Higher-order immunoglobulin repertoire restrictions in CLL: the illustrative case of stereotyped subsets 2 and 169.
    Blood. 2021;137:1895-1904.
    PubMed         Abstract available


    Bone Marrow Transplant

  6. CRUIJSEN M, Hilberink JR, van der Velden WJFM, Jansen JH, et al
    Low relapse risk in poor risk AML after conditioning with 10-day decitabine, fludarabine and 2 Gray TBI prior to allogeneic hematopoietic cell transplantation.
    Bone Marrow Transplant. 2021;56:1964-1970.
    PubMed         Abstract available

  7. MIKULSKA M, Tridello G, Hoek J, Gil L, et al
    Legionellosis after hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2021 May 22. pii: 10.1038/s41409-021-01333.
    PubMed         Abstract available

  8. GALE RP, Schiffer CA, Lazarus HM
    Granulocyte transfusions in haematopoietic cell transplants and leukaemia: the phoenix or beating a dead horse?
    Bone Marrow Transplant. 2021;56:2046-2049.
    PubMed        

  9. JENTZSCH M, Grimm J, Bill M, Kupper J, et al
    Measurable residual disease of canonical versus non-canonical DNMT3A, TET2, or ASXL1 mutations in AML at stem cell transplantation.
    Bone Marrow Transplant. 2021 Jul 15. pii: 10.1038/s41409-021-01407.
    PubMed        

  10. KOBAYASHI S, Kanda Y, Konuma T, Inamoto Y, et al
    Outcomes of third allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute leukemia after a second transplantation.
    Bone Marrow Transplant. 2021 Oct 8. pii: 10.1038/s41409-021-01485.
    PubMed         Abstract available

  11. YANADA M, Ota S, Mukae J, Nara M, et al
    Autologous hematopoietic cell transplantation during second or subsequent complete remission of acute promyelocytic leukemia: a prognostic factor analysis.
    Bone Marrow Transplant. 2021 Oct 13. pii: 10.1038/s41409-021-01501.
    PubMed         Abstract available

  12. BAZARBACHI A
    Exciting times ahead for older patients with acute myeloid leukemia: azacitidine and venetoclax followed by allogeneic hematopoietic cell transplantation.
    Bone Marrow Transplant. 2021 Oct 13. pii: 10.1038/s41409-021-01474.
    PubMed        

  13. RUGGERI L, Vago L, Eikema DJ, de Wreede LC, et al
    Natural killer cell alloreactivity in HLA-haploidentical hematopoietic transplantation: a study on behalf of the CTIWP of the EBMT.
    Bone Marrow Transplant. 2021;56:1900-1907.
    PubMed         Abstract available


    Cancer

  14. ALDOSS I, Otoukesh S, Zhang J, Mokhtari S, et al
    Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia.
    Cancer. 2021 Oct 11. doi: 10.1002/cncr.33967.
    PubMed         Abstract available


    Eur J Immunol

  15. FINK A, Hung E, Singh I, Ben-Neriah Y, et al
    Immunity in acute myeloid leukemia: where the immune response and targeted therapy meet.
    Eur J Immunol. 2021 Oct 14. doi: 10.1002/eji.202048945.
    PubMed         Abstract available


    Exp Hematol

  16. MACBETH KJ, Chopra VS, Tang L, Zheng B, et al
    Combination of azacitidine and enasidenib enhances leukemic cell differentiation and cooperatively hypomethylates DNA.
    Exp Hematol. 2021;98:47-52.
    PubMed         Abstract available

  17. YOKOMIZO-NAKANO T, Sashida G
    Two faces of RUNX3 in myeloid transformation.
    Exp Hematol. 2021;97:14-20.
    PubMed         Abstract available

  18. DI GENUA C, Nerlov C
    To bi or not to bi: Acute erythroid leukemias and hematopoietic lineage choice.
    Exp Hematol. 2021;97:6-13.
    PubMed         Abstract available


    Int J Hematol

  19. IKAWA Y, Takenaka M, Sakai Y, Noguchi K, et al
    Utility of 18F-FDG-PET for detecting acute lymphoblastic leukemia: a case series of pediatric acute lymphoblastic leukemia without hematological symptoms.
    Int J Hematol. 2021 Oct 13. pii: 10.1007/s12185-021-03232.
    PubMed         Abstract available


    J Clin Oncol

  20. SHAH NN, Lee DW, Yates B, Yuan CM, et al
    Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL.
    J Clin Oncol. 2021;39:1650-1659.
    PubMed         Abstract available


    J Natl Cancer Inst

  21. LIPSYC-SHARF M, Zhang S, Ou FS, Ma C, et al
    Survival in Young-Onset Metastatic Colorectal Cancer: Findings from Cancer and Leukemia Group B (Alliance)/SWOG 80405.
    J Natl Cancer Inst. 2021 Oct 12. pii: 6390822. doi: 10.1093.
    PubMed         Abstract available


    Leuk Lymphoma

  22. LI S, Ji Y, Peng Y, Kota V, et al
    Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with acute myeloid leukemia meeting ineligibility criteria for high intensity chemotherapy.
    Leuk Lymphoma. 2021 Oct 13:1-11. doi: 10.1080/10428194.2021.1973669.
    PubMed         Abstract available

  23. COCHRANE T, Enrico A, Gomez-Almaguer D, Hadjiev E, et al
    Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial.
    Leuk Lymphoma. 2021 Oct 11:1-11. doi: 10.1080/10428194.2021.1986217.
    PubMed         Abstract available


    Leukemia

  24. VAN DIJK AD, Griffen TL, Qiu YH, Hoff FW, et al
    RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences.
    Leukemia. 2021 Oct 8. pii: 10.1038/s41375-021-01438.
    PubMed         Abstract available


    Oncogene

  25. ZHANG J, Zhai J, Wong CC, Chen H, et al
    A novel amplification gene PCI domain containing 2 (PCID2) promotes colorectal cancer through directly degrading a tumor suppressor promyelocytic leukemia (PML).
    Oncogene. 2021 Oct 8. pii: 10.1038/s41388-021-01941.
    PubMed         Abstract available


    PLoS One

  26. PARKER C, Zomer E, Liew D, Ayton D, et al
    Characterising experiences with acute myeloid leukaemia using an Instagram content analysis.
    PLoS One. 2021;16:e0250641.
    PubMed         Abstract available

  27. ONO R, Masuya M, Inoue N, Shinmei M, et al
    Tet1 is not required for myeloid leukemogenesis by MLL-ENL in novel mouse models.
    PLoS One. 2021;16:e0248425.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: